All the Active Ingredient Drugs
Protein Kinase Inhibitor. Lenvatinib (as mesilate) 4 mg, 10 mg. HARD CAPS.: 30. Different. thyroid carcinoma (DTC): 24 mg (two 10 mg caps. and one 4 mg cap.) once dly. The dly. dose is to be modified as needed accord. to the dose/toxicity manag. plan.
Clear cell renal cell carcinom. (RCC): 18 mg (one 10 mg cap. and two 4 mg caps.) once dly. in comb. with 5 mg of everolimus once dly. The dly. doses of lenvatinib and, if necessary, everolimus are to be modified as needed accord. to the dose/toxicity manag. plan.
Hepatocellular Carcinoma (HCC): 8 mg (two 4 mg caps.) once dly. for pts. with a bdy. weight of<60 kg & 12 mg (three 4 mg caps.) once dly. for pts. with a body weight of≥60 kg. Dose adjust. are based only on toxicit. observed and not on body weight changes during tmt. The dly. dose is to be modified, as needed, according to the dose/toxicity manag. plan.
Dose adjust. and Discont. for HCC Manag. of some ADR's may require dose interrupt., adjust., or discont. See lit.
Tmt. of adult pts. with progress., locally advance. or metastat., differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refract. to radioact. iodine (RAI).
In comb. with everolimus for the tmt. of adult pts. with advanc. clear cell renal cell carcinom. (RCC) follow. one prior vascul. endothelial growth factor (VEGF)-targeted ther.
Indicated as monother. for the tmt. of adult pts. with advanc. or unresect. hepatocellular carcinom. (HCC) who have received no prior system. ther.
C/I: Hypersens. Lact.
